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ABSTRACT 
Type 1 Interferon (IFN-1) promotes regulatory T-cell function to suppress inflammation 
in the mouse intestine, but little is known about IFN-1 in the human gut. We therefore 
assessed the influence of IFN-1 on CD4+ T-cells isolated from human colon tissue 
obtained from healthy controls or patients with inflammatory bowel disease (IBD). 
Immunofluorescent imaging revealed constitutive expression of IFN in human 
intestinal tissue, and colonic T-cells were responsive to exogenous IFN-1 as assessed 
by phosphorylation of Signal Transduction and Activator of Transcription 1 (pSTAT1) 
and induction of Interferon Stimulated Genes (ISGs). Unlike their blood counterparts, 
intestinal T-cells from non-inflamed regions of IBD colon displayed enhanced 
responsiveness to IFN-1, increased frequency of pSTAT1+ cells, and greater induction 
of ISGs upon IFN-1 exposure in vitro.  
In healthy tissue, antibody neutralisation of IFN selectively reduced T-cell production 
of the pro-regulatory cytokine IL-10 and increased IFNγ synthesis. In contrast, 
neutralisation of IFN in IBD tissue cultures increased the frequency of T-cells 
producing inflammatory cytokines but did not alter IL-10 expression. These data 
support a role for endogenous IFN-1 as a context-dependent modulator of T-cell 
function that promotes regulatory activity in healthy human intestine, but indicate the 
IFN-1/STAT1 pathway is dysregulated in inflammatory bowel disease. 
 
 
 
 
 
 
 
 
INTRODUCTION 
In the healthy intestine, regulatory mechanisms limit T-cell responsiveness to the 
commensal microbiota and environmental antigens in order to maintain homeostasis, 
but dysregulation of these mechanisms can lead to pathological inflammation and 
development of inflammatory bowel disease (IBD). Accordingly, intestinal T-cells 
remain one of the main targets for IBD therapy1, but the endogenous factors that 
regulate T-cell activity in the human gut are not fully understood.  
The balance of T-cell regulatory and effector functions are determined partly during 
priming in gut-associated lymphoid tissue or mesenteric lymph nodes. Signals derived 
from the activating dendritic cell (DC) and local environment can influence the 
differentiation of naive CD4+ T-cells towards a variety of effector or regulatory fates. 
However, it is now clear that T-cell properties are not fixed during priming but instead 
these cells retain functional plasticity and their function can be modified by signals 
encountered later upon homing to the intestinal mucosa.2, 3, 4  
Type 1 Interferon (IFN-1), predominantly IFN and IFN, has emerged as a potent 
context/timing-dependent modifier of T-cell function.5 IFN-1 binds to the IFN-1 receptor 
(IFNAR) and can differentially activate members of the Signal Transduction and 
Transcription (STAT) family to determine downstream cytokine production.6 For 
example, in murine T-cells IFN-1 signalling via STAT1 inhibits IFNγ production, 
whereas signalling via STAT4 instead promotes IFNγ.7  
IFN-1 limits viral replication in acute infection, but can also contribute to viral 
persistence in chronic infection models via the induction of IL-10 producing CD4+ T-
cells. This suggests a potential role for IFN-1 in chronic  
T-cell-driven inflammatory disorders.8, 9, 10 In mice, constitutive low-level production of 
IFN occurs in several tissues even in the absence of viral infection.11 This  suggests 
that, at least in mice, endogenous IFN-1 may regulate T-cell expression of STAT 
proteins and control responsiveness to subsequent stimuli.6 In murine models, IFNAR 
deficiency increases susceptibility to Dextran Sodium Sulphate (DSS) colitis12, 
whereas administration of IFN-1 can ameliorate DSS colitis via a mechanism that 
depends on TLR9/bacterial DNA13, 14. However, reports that local delivery of IFN-1 by 
a transgenic Lactobacillus acidophilus led to increased severity of DSS colitis12, 
underscore the complex role of IFN-1 in maintaining mucosal integrity. 
In a T-cell transfer model of colitis, IFN-1 signalling induced by poly(I:C) can ameliorate 
gut inflammation via a mechanism thought to require both FoxP3+ regulatory T-cells15, 
16, and IFNAR expression by the grafted colitogenic T-cells17. In human multiple 
sclerosis, therapeutic administration of IFN-1 promotes T-reg IL-10 expression while 
restricting IL-17-driven inflammation18. While genome-wide association studies have 
detected IFNAR variants associated with increased risk for developing IBD19, IFN-1 
therapy displayed only limited efficacy in human IBD20. Given that constitutive 
expression and function of IFN-1 in human intestinal immunity is not known, we aimed 
to determine how IFN-1 influences signalling pathways at single-cell resolution in 
defined populations of intestinal T-cells in health and IBD. 
 
RESULTS 
IFN-1 is constitutively expressed in human colon and modulates the function of 
intestinal T-cells 
To assess whether IFN-1 influences T-cell function in the human intestine, we first 
sought evidence that T cells are responsive to IFN-1 in human colon. To do this, we 
assessed mRNA expression levels of interferon stimulated genes (ISGs; myxovirus 
resistance A - MxA and 2'-5' oligoadenylate synthetase - 2'5'OAS) in cells migrated 
out of human colonic biopsy tissue during overnight incubation in the presence or 
absence of IFN-1. The intestinal T-cells were then isolated by FACS sorting and 
subjected to qRT-PCR. Alternatively, cells were obtained without IFN-1, but then 
exposed or not to brief (15 minute) IFN-1 stimulation, and then permeabilized for 
assessment of pSTAT1 expression. Both approaches revealed that IFN-1 treatment 
of either healthy colon or IBD tissue increased intestinal T-cell expression of MxA 
(median 30-fold, figure 1A) and 2'5'OAS (median 50-fold, figure 1B), and induced a 
~10-fold increase in the frequency of CD4+ T-cells expressing pSTAT1 (Figure 1D, 
representative FACS plots figure 1C).  
We next sought to identify direct evidence of IFN-1 in the human colon, focusing on 
the IFN isoform thought to co-ordinate many key effects of IFN-1 6. Technical 
challenges have hampered previous attempts to directly detect IFN-1 in human 
tissues, but a recent publication successfully observed IFNβ expression in human skin 
using IHC analysis of freshly frozen clinical samples 21. We therefore used a similar 
IHC approach to visualize endogenous IFNβ in colonic tissue. IFNβ was detected, 
distributed in the epithelium and also throughout the lamina propria in close 
association with intestinal T-cells, in both controls and IBD patients (Figure 1 E-F and 
supplementary Figure 1).  
 
We next sought evidence that human intestinal T-cells can be influenced by IFN-1 
exposure in situ. We detected pSTAT1 in both naïve and memory subsets of CD4+ T-
cells both before and after IFN-1 stimulation, but the frequency of pSTAT1+ cells was 
significantly higher in the stimulated memory cell population (supplementary Figure 2). 
Accordingly, expression of the T-cell activation marker CD69 was detected only 
among CD45RA- memory cells, and the CD69+ population included a higher 
frequency of pSTAT1+ cells, suggesting increased responsiveness to IFN-1 
specifically in the activated memory T-cell compartment (supplementary Figure 3). 
Since these cells exhibited low-level 'constitutive' phosphorylation of STAT1 and 
expression of ISGs even in the absence of IFN-1 supplementation (Figure 1 A-D), we 
next assessed whether exposure to endogenous IFN-1 during the cell isolation 
process was sufficient to induce STAT1 signalling. To do this, we established walk-
out cultures in the presence or absence of neutralising anti-IFN antibody and 
assessed T-cell expression of total STAT1 and pSTAT1. As phosphorylation is a brief 
process and the neutralisation was conducted over the 24 hour walk-out period, it was 
felt more likely to detect an effect in total STAT1 expression, which is known to be 
influenced by IFN-1 signalling 6. Neutralisation of IFNsignificantly reduced the 
frequency of U-STAT1+ CD4+ T-cells detected (Figure 2 A and B), suggesting that 
constitutively produced IFN was biologically active in these cultures. Additionally, 
these cells had reduced responsiveness to further IFN-1 stimulation with decreased 
frequency of pSTAT1+ cells (Figure 2 C and D). This is consistent with endogenous 
IFNβ priming CD4+ T cells in their responsiveness to IFN-1. In contrast, addition of 
neutralising anti-IFN did not significantly alter STAT1 phosphorylation or total STAT1 
levels (data not shown). Collectively these data support a role for IFN produced 
constitutively within human intestinal tissue as a potential modulator of gut T-cell 
function, signalling at least in part via STAT1 activation. 
 
Phosphorylation of STAT1 and IFNresponsiveness are enhanced in intestinal 
CD4+ T-cells from IBD patients. 
In order to assess whether IFN-1:STAT1 signalling is altered in human IBD, we next 
compared CD4+ T-cell responsiveness to IFNand pSTAT1 expression between IBD 
patients and control donors. To do this, we focused our analyses on cells isolated from 
macroscopically and histologically non-inflamed areas of colon in order to exclude 
signalling signatures associated with active inflammation. Even in unstimulated tissue 
cultures, we observed marked expression of pSTAT1 among CD4+ T-cells isolated 
from the intestinal mucosa (Figures 1 C and D), although the total frequency of 
pSTAT1+ cells was significantly higher in colonic tissue from IBD patients (Figure 1D). 
Upon supplementation with exogenous IFN-1, both IBD colon samples and control 
tissues exhibited ~10-fold increases in the proportion of derivative cells containing 
pSTAT1 (Figure 1D). Similar data were obtained in parallel analysis of samples of 
inflamed mucosal tissue from IBD patients, although the total proportion of pSTAT1+ 
cells detected was lower (Supplementary Figure 4). These data indicated that under 
both resting and inflammatory conditions, CD4+ T-cells in IBD colon exhibit increased 
STAT1 activation compared with their counterparts in control tissue samples. We 
therefore proceeded to investigate whether the increased levels of pSTAT1 detected 
in CD4+ T-cells in IBD tissue could indicate enhanced Th1 polarization, as described 
in an earlier report22. However, our analyses revealed that pSTAT1 was expressed at 
comparable levels in both Tbet+ (Th1 cells) and Tbet- subsets of gut CD4+ T-cells 
(Figure 3A-C), indicating that pSTAT1 was not a surrogate marker of Th1 cells in this 
setting.  
Collectively these data demonstrated that STAT1 phosphorylation and putative IFN-1 
signalling were modulated in T-cells that migrated out of IBD colon, irrespective of 
whether the tissue was overtly inflamed. Conceptually, these effects could reflect 
intrinsic T-cell properties, exposure to soluble factors released by the cultured tissue, 
or a combination of these effects.  
To test for the presence of IBD-associated factors that might initiate STAT1 
phosphorylation, we assessed the ability of IBD tissue culture supernatants to induce 
pSTAT1 in CD4+ T-cells derived from control colon tissue. Despite extensive 
investigation, we found no consistent evidence that soluble factors released from IBD 
tissue could up-regulate pSTAT1 in healthy colonic CD4+ T-cells (data not shown). 
These findings indicated that IBD-associated changes in STAT1 phosphorylation and 
responsiveness to IFN-1 were at least in part due to intrinsic properties of the T-cells. 
Accordingly, we observed that gut T-cells from IBD patients exhibited greater IFN-1-
induced ISG expression (Figure 3D-E). Furthermore, we detected a strong trend 
towards reduced expression of the STAT1 regulator SOCS1 in intestinal T-cells freshly 
isolated from IBD patients (Figure 3F). Taken together, these data indicate that altered 
IFN-1 responsiveness and STAT1 phosphorylation in IBD are at least in part due to 
changes in gut T-cell-intrinsic properties. 
 
IFN:STAT1 signalling exerts differential effects on T-cell function in healthy 
tissue and IBD colon  
When we assessed the ability of IFN-1 to activate alternative STAT family members 
in intestinal CD4+ T-cells, we observed marked phosphorylation of both STAT3 (2-fold 
increase) and STAT5 (4-fold increase) in response to IFN-1 exposure, but we did not 
detect any differences between patients and controls either at baseline or in the 
cytokine-treated cultures (Figure 4A). These data suggested that differential effects of 
IFNβ on STAT activation in  
T-cells from IBD patients were specific to STAT1. We therefore proceeded to 
investigate whether the increased IFN-1 responsiveness and STAT1 phosphorylation 
observed in IBD patient T-cells was restricted to the gut or reflected system-wide 
changes in T-cell function. To do this, we analysed CD4+ T-cells in peripheral blood 
and observed that the trace numbers of pSTAT1+ cells were significantly increased 
by IFN-1 stimulation, particularly within the CD45RA- memory/effector compartment 
(32.1%±22 pSTAT1+ post stimulation) in CD45RA- cells versus 18.2%±15.2 in 
CD45RA+ cells, p<0.05 ANOVA). However, we observed no significant difference in 
IFNβ responsiveness between IBD patients and controls even when comparing gut-
homing CD4+ T-cells (7 integrin+) with CD4+ T-cells targeted to other sites (7-
negative; Figure 4B). These data indicated that IBD-associated changes in IFN-1 
responsiveness and pSTAT1 expression of intestinal CD4+ T-cells are local effects 
that do not reflect systemic alterations in these patients. 
 
There is increasing evidence from murine models that constitutive IFN expression 
can support regulatory T-cell responses15, 16, but the function of this cytokine in the 
human intestine is currently unknown. To address this question, we obtained T-cells 
from colonic biopsy tissue cultured in the presence or absence of neutralising anti-
IFNantibody and measured cytokine production and expression of master regulator 
transcription factors upon re-stimulation with anti-CD3 and anti-CD28. Addition of anti-
IFN to the biopsy cultures did not alter T-cell expression of the transcription factors 
T-bet or FoxP3 as assessed by intracellular staining (Figure 5A, B), and RORγt 
expression was very low throughout (data not shown). Nonetheless, intracellular 
cytokine staining of cells isolated from healthy tissue revealed that anti-IFN treatment 
induced a significant decrease in the frequency of CD4+ T-cells producing IL-
10Figure 5C, with a trend towards an increased frequency of IFNγ-producing cells 
(Figure 5D), accompanied by a significant increase in supernatant concentration of 
IFNdetected by ELISA (Figure 6B). TNF and IL-17A production were also observed, 
although IFN neutralisation failed to alter the amount detected either by intracellular 
staining (Figures 5E and 5F) or ELISA measurementFigures 6C and 6D)These 
findings suggest a potentially important role for endogenous IFNin modulating the 
balance of IFN and IL-10 production by local T-cells in healthy tissues to favour the 
expression of anti-inflammatory cytokines. This effect is likely due to functional 
modulation by environmental signals rather than altered T-cell differentiation fates, 
since the transcription factor profiles observed were not altered by IFN-1 exposure. 
 
These ‘pro-regulatory’ effects of IFN treatment in control tissues were absent when 
we repeated these experiments using colon samples from IBD patients, even though 
the tissues analysed were obtained from non-inflamed regions of the intestine 
(macroscopically and histologically normal; Figures 5 and 6).  
In IBD biopsy organ culture, treatment with neutralising anti-IFN induced an increase 
in the proportion of intestinal T-cells producing IFN, TNF and IL-17A, and trend 
towards increased production of IL-10 (Figure 5A), accompanied by a significant 
increase in supernatant IL-10 levels as assessed by ELISA (Figure 6A). Consistent 
with previous reports, T-cells expressing T-bet or Foxp3 were more frequent in IBD 
tissue than control samples (Supplemental Figure 5)23, 24, but as observed in healthy 
tissue expression of these transcriptional regulators was not altered by neutralisation 
of IFNfigures 5A and 5B). Therefore, endogenous IFN has a pro-regulatory effect 
in healthy tissue, where this cytokine promotes IL-10 production, whereas in IBD our 
data indicate that IFN instead restricts a number of effector T-cells producing 
cytokines in the intestine.  
DISCUSSION 
This study reports that endogenous IFN promotes STAT1 phosphorylation in human 
intestinal T-cells to exert pro-regulatory effects in the healthy gut. We also present 
evidence that this axis is disrupted in IBD, where endogenous IFN instead restricts 
effector T-cell cytokine responses, even when assessing macroscopically and 
histologically non-inflamed areas of the gut. 
 
We observed that T-cells isolated from human intestinal tissue were responsive to 
IFN-1 in vitro, as demonstrated by phosphorylation of multiple STAT signalling 
proteins and marked induction of ISG expression. The induction of ISG expression 
was on total (CD3+) T cells and the differential contribution of CD8 and CD4 
populations cannot be determined. We also detected that a proportion of T-cells 
migrating out of cultured biopsy tissue expressed the phosphorylated form of STAT1, 
which is the primary family member involved in IFN-1 signalling. This finding 
suggested that gut T-cells may be exposed to IFN cytokine in situ, and accordingly 
we observed for the first time that IFN is present in human colonic tissue. It is unclear 
what the source of the IFN-1 is although the epithelium appears to be important and 
this would be an interesting area for further research. 
There is increasing evidence from murine models that constitutive production of IFN-
1, and IFN in particular, can exert immunoregulatory effects15, 16, 25. Consistent with 
this concept, neutralisation of IFN in biopsy cultures from healthy donors significantly 
reduced the generation of IL-10+ T-cells, whereas the frequency of IFNT-cells and 
quantity of IFN detected in the culture supernatants were increased.  
The differences between the intracellular staining of the intestinal T cells compared to 
the ELISA data may be due to the contribution of other cell types in the supernatants 
and their differential response to IFN It is likely that other IFN-1 subtypes are also 
present in the environment and it is not possible to conclude about the functional 
importance of all IFN-1 in this system. However, the overall findings are consistent 
with data from the murine T-cell transfer model of colitis, in which IFN-1 was found to 
be critical for maintaining regulatory T-cell function15, 16. However, in contrast with the 
experimental models, our data did not demonstrate any effect of IFN-1 on expression 
of FoxP3, which is less tightly linked to regulatory function in the human system26.  
 
It has been suggested that the IFN-1 effects on T-cell function are context dependent27 
Consistent with this concept, our data demonstrate that the effects of IFN differ in 
healthy and IBD mucosa.  Our findings are best explained by plasticity of intestinal T 
cells and their responsiveness to local environmental signals.  Our analysis provided 
no evidence for altered differentiation to major T cell fates as defined by expression of 
master transcriptional regulators. 
Phosphorylation of STAT1 in gut T-cells was demonstrated within 15min of exposure 
to IFN-1, suggesting a direct effect of IFN-1 on T cells, but it is not possible to exclude 
a contribution from other cell types in these cultures to many of the effects measured. 
The varied results obtained by ELISA analysis of supernatants from both control and 
IBD tissue cultures (Figures 6 and 8) do suggest a differential role of IFN-1 on non-T-
cells, although the small tissue samples available precluded further investigation of 
this issue. Indeed, an early study on the role of interferon on LPMCs suggested that, 
in regards to cytotoxicity, LPMCs from IBD patients can be relatively hyporesponsive 
to exogenous interferon28.  
 
Several of our observations indicate altered IFN-1 responsiveness and STAT1 
phosphorylation of gut T-cells in IBD. For this analysis, we focused primarily on tissue 
sampled from macroscopically and histologically non-inflamed areas of intestine in 
order to identify underlying immunoregulatory changes that might otherwise be 
masked by ongoing inflammatory processes.  
The frequency of pSTAT1+ CD4+ T-cells detected was higher in non-inflamed IBD 
colon than in control tissue both in unstimulated cultures and after exposure to IFN-1 
in vitro. This difference was specific for STAT1 in the intestinal mucosa, since we were 
unable to identify any modulation of alternative IFN-1-sensitive STATs or detect any 
changes in T-cells derived from the blood. Indeed, we were also unable to induce 
phosphorylation of STAT1 in control T-cells upon incubation with the culture 
supernatant of IBD biopsies, suggesting that enhanced pSTAT1 expression by IBD T-
cells is an intrinsic property of these cells rather than being conferred by a soluble 
factor. 
 
Previous studies have typically focused on analysing STAT expression in whole 
samples of inflamed IBD tissue (containing numerous different cell types). Instead, we 
have for the first time used a novel phosflow-based method to measure the 
phosphorylated forms of STAT proteins at the single cell level in distinct subsets of 
human leukocytes in the absence of overt mucosal inflammation. Using this approach, 
we observed an increased frequency of pSTAT1+ intestinal CD4+ T-cells in tissue 
from IBD patients, consistent with a previously shown trend for increased pSTAT1 
levels in whole tissue homogenates, and increases in total STAT1 protein identified in 
CD4+ lamina propria cells29. However, we did not observe the previously reported 
increases in STAT3 expression and phosphorylation in IBD29, 30, which may reflect 
cell-type specific differences or could perhaps be attributed to our approach of 
analysing non-inflamed tissue.  
 
In addition to increased expression of pSTAT1, intestinal CD4+ T-cells from non-
inflamed IBD intestinal tissue were significantly more responsive to IFN-1 stimulation 
as assessed by induction of ISG expression. Given the direct relationship between 
exposure to IFN-1 and expression of this gene set, this observation again suggests 
direct effects of IFN-1 on the T-cell population. Suppressor of Cytokine Signalling 1 
(SOCS1) is a major regulator of STAT1 signalling in T-cells, and conditional KO of 
Socs1 in murine T-cells has been shown to exacerbate colitis31. SOCS1 is induced by 
IFN-1 and acts via numerous mechanisms as part of a negative feedback loop in IFN-
1-STAT1 signalling32. In our study, there was a strong trend towards reduced SOCS1 
expression in intestinal T-cells freshly isolated from non-inflamed IBD tissue; we 
observed a corresponding increase in total STAT1 levels in these cells. It is therefore 
likely that reduced SOCS1 control of STAT1 signalling contributes to increased IFN-1 
sensitivity of gut T-cells in IBD. Consistent with this altered responsiveness to IFN-1, 
we further observed that neutralization of IFN during IBD biopsy culture increased 
the frequency of derivative T-cells producing IFN, TNF or IL-17A. These data 
suggest that the non-inflamed IBD mucosa represents a modified signalling 
environment in which endogenous IFN acts to restrain production of pro-
inflammatory cytokines rather than promoting IL-10 expression, perhaps to prevent 
the development of overt inflammation. We also detected a strong trend towards 
reduced ISG expression by gut T-cells when measured directly after isolation from IBD 
tissues compared with control tissue. Based on these observations, we propose that 
in IBD tissue the constituent T-cells exhibit altered responsiveness to endogenous 
IFN and other subsequent environmental signals, which could in part explain the 
seemingly conflicting early data on the role these cytokines play in IBD.  
While the efficacy of IFN-1 treatment in IBD has been largely disappointing20, there 
have been promising early results from a phase 1 trial of UC patients treated with the 
IFN-1-inducing TLR9 agonist DIMS015033. More recently, it has been demonstrated 
that patients with either UC or Crohn’s disease have a distinct ‘virobiota’ compared to 
household controls34, suggesting that IFN-1 may be an important factor in the complex 
interactions between viruses, bacteria and the host immune system during the 
pathogenesis of IBD.  
 
In summary, this study demonstrates that human colon constitutively expresses IFNβ, 
which has a selective STAT1-dependent pro-regulatory effect on cytokine production 
by intestinal T-cells. This finding is consistent with mouse models in which IFN-1 
signalling via STAT1 inhibits IFNγ production35. Our observations are also in 
agreement with the concept that the balance of STAT proteins and their activation 
determines the outcome of subsequent exposure to IFN-1 and other local triggers. 
Specifically, in this view IFN-1 maintains a basal repertoire STAT expression that 
forms a platform for specific T-cell responses6.  
This IFN-1-shaped level of T-cell responsiveness would be an important determinant 
of local immune responses against viruses and other pathogens in the human intestine 
while preventing an excessive inflammatory response. 
 
METHODS 
Patient samples and cell isolation 
Intestinal tissues were collected from patients with IBD during endoscopy or surgery, 
and control tissues were collected from subjects who were undergoing follow-up 
because of rectal bleeding, altered bowel habits, or cancer. The diagnosis for each 
patient was made using clinical parameters, radiographic studies, and histological 
criteria. All tissue and blood donors gave informed written consent, and the study was 
approved by the local research ethics committee. Patient information is presented in 
supplementary information.  
 
 
Cells were extracted from intestinal tissue by enzymatic digestion or “walk-out” culture 
as previously described 36, 37, 38. Briefly, the tissue was treated with 1mmol/L 
dithiothreitol (Sigma-Aldrich St. Louis, MO, USA) to remove faeces and mucus, 
followed by 1mmol/L EDTA (Sigma-Aldrich) in Hank's balanced salt solution (Sigma-
Aldrich) to remove epithelium. Digestion was by 1 mg/mL collagenase D (Roche 
Applied Science Penzberg, Upper Bavaria, Germany) in HEPES-buffered RPMI 1640 
medium (Sigma-Aldrich) containing 2% foetal calf serum (PAA Little Chalfont, UK) and 
20 μg/mL deoxyribonuclease I (Roche Applied Science). A lamina propria (LP) cell 
suspension was passed through a 40μm cell strainer. Alternatively, biopsies were 
cultured for “walk-out” following EDTA processing. The denuded tissue was placed in 
0.5mL complete medium (RPMI1640 Dutch Modification supplemented with 2mM L-
glutamine, 100U/mL penicillin, 100μg/mL streptomycin, 100μg/mL gentamicin (all 
Sigma-Aldrich) and 10% heat-treated (56 °C for 30 minutes) foetal calf serum (FCS; 
PAA). Cultures were established in 24 well plates (Becton Dickinson) at one biopsy in 
0.5 mL of medium per well and placed in a humidified incubator at 37 ºC with 5% CO2 
in air. In some experiments the medium was supplemented with IFNβ (Peprotech) at 
1000IU/ml or with an equal volume of the diluent Phosphate Buffer Saline (PBS) as a 
control. Alternatively, human anti-IFNβ antibody or an isotype-matched mouse IgG1 
control antibody (both from Biolegend) were added at 1 µg/ mL (Biolegend) The 
biopsies were then discarded after 48hrs culture and egressed cells collected from the 
remaining medium by centrifugation at 400 x g for 5 minutes. Typically, 80% of viable 
cells isolated from non-inflamed or control samples were CD3+, and 75% of these 
cells were CD4+. Viability was assessed using Live/Dead staining. 
 
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy volunteer 
donors or patients by centrifugation over Ficoll-Paque PLUS (GE Healthcare Little 
Chalfont, UK) at 650g for 20min.  
 
 
Antibody Labelling and Flow Cytometry 
Cells were incubated with monoclonal antibodies on ice for 15 minutes in 100 μL 
fluorescence-activated cell sorting (FACS) buffer (phosphate-buffered saline with 
2%v/v FCS mmol/L EDTA and 0.2% sodium azide), washed by centrifugation, and 
fixed in 1% (wt/vol) paraformaldehyde. Cells were acquired on a FACSCanto II (BD 
Biosciences), using CellQuest software (BD Biosciences) and analyzed using WinList 
6.0 software (Verity Topsham, ME). Positively stained cells were identified relative to 
isotype-matched control antibody staining. A full list of the monoclonal antibodies used 
is provided in Supplementary Materials.  
 
Analysis of phosphorylated antigens by flow cytometry 
A technique for measuring intracellular phosphorylated antigens in single cells was 
developed and optimized as part of this study. LPMCs isolated by walk-out were re-
suspended in 100µL complete medium with gentamicin in 5mL FACS tubes and either 
left unstimulated or stimulated with 40,000 IU/mL IFNα2A (Peprotech), for 15min in a 
37°C water bath. The cells were then fixed by addition of an equal volume of 4 % w/v 
paraformaldehyde (PFA) for 10min in a 37°C water bath. 
 
The fixed cells were washed by centrifugation in PBS and then incubated in 1mL of 
70% cold methanol (VWR, USA) on ice for 30min for permeabilisation. The cells were 
washed twice in FACS buffer and then  
re-suspended in 100µL FACS buffer for simultaneous cell surface and intracellular 
antibody labelling. Cells were labelled as appropriate and incubated for 30-60min at 
room temperature. After one further wash with FACS buffer the cells were re-
suspended in 300µL of FACS buffer and analysed by flow cytometry as described. 
 
Stimulation of T-cells for cytokine analysis 
LPMCs were cultured in 200μL complete medium in 96 well plates (Beckton 
Dickinson), and Low Endotoxin Azide Free (LEAF) anti-CD3 and anti-CD28 antibodies 
(Biolegend) were added each at a final concentration of 1μg/mL. The plates were put 
in a humidified incubator at 37°C with 5% CO2 in air for 20h. After 20 hours the cells 
were collected into 5mL FACS tubes, and the Golgi-blocking agent monensin (VWR) 
was added at 3μM final concentration and the tube contents mixed thoroughly. The 
FACS tubes were replaced in the incubator for 4 hours. Cells were then collected and 
processed by flow cytometry after centrifugation and supernatants were stored at -
80°C. 
 
Isolation of intestinal or peripheral T-cells by flow sorting 
LPMCs, collected by walk-out technique, were washed by addition of excess FACS 
buffer, centrifugation at 400 x g for 5 min and discarding of supernatant. The cells were 
then resuspended into 100 μL filter sterilised (0.2 micron) modified FACS buffer 
(lacking sodium azide) and incubated with relevant monoclonal antibodies for 15 
minutes on ice protected from light. Cell populations within LPCs were isolated by flow-
sorting using a FACS Aria cytometer (Becton Dickinson). In order to sort only viable 
T-cells, the agent 7-amino-actinomycin D (7-AAD; Biolegend) was used in 
combination with CD3+ labelling.  
 
Quantitative Real-Time Polymerase Chain Reaction 
RNA extraction and reverse transcription were performed using the RNeasy Micro Kit 
and QuantiTect Reverse Transcription Kit, respectively. Quantitative real-time 
polymerase chain reaction (PCR) was performed using the QuantiFast SYBR Green 
PCR Kit (all from Qiagen Venlo, Limburg, Netherlands) on a 7500 Real-Time PCR 
System (Applied Biosystems Foster City, CA). Full primers are listed in Supplementary 
Materials. Expression data were normalized to GAPDH using the 2−ΔCt method. 
 
Multiplex ELISA 
Measurement of TNFα, IL-10, IFNγ, and IL-17A in culture supernatants was performed 
using the FlowCytomix™ Multiplex Kit (eBioscience) according to the manufacturer’s 
instructions. Data was acquired on a Canto II Flow Cytometer (BD Bioscience), set up 
as recommended by the kit manufacturer and data analysed using FlowCytomixPro™  
(eBioscience) software. 
 
Immunohistochemistry 
Colonic biopsies were snap frozen in liquid nitrogen. Slides were prepared by the 
pathology service at the Royal London Hospital (Barts Health, UK). Slides were fixed 
with addition of 1 mL of PFA 4%. 1 mL blocking serum (5% BSA, 0.1% Tween in PBS) 
was added followed by addition of primary antibodies. The antibodies used were as 
shown in supplementary table XXX. Secondary antibodies were applied: AF555 goat 
anti-mouse IgG (Invitrogen, USA), and/or AF488 donkey anti-rabbit IgG (Invitrogen, 
USA). Mounting medium was with DAPI (Vectorshield, Vector Laboratories, USA). 
 
Analysis was performed with a Research Systems Microscope BX61 (Olympus), with 
digital image capture at 100x (standard) or 200x (high power) using the software 
system SmartCapture v3.0 (Digital Scientific, UK).  
 
Statistics 
Statistical analyses were performed using SigmaStat 3.5 (Systat Software San Jose, 
CA). Comparisons between 2 groups of paired, normally and non-normally distributed 
data were analyzed using Paired t test, Student t test and Signed rank test, 
respectively. Data sets of more than 2 groups were compared by analysis of variance 
(ANOVA) with pairwise comparisons by Holm–Sidak test. P < 0.05 was regarded as 
statistically significant. 
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 Figure Legends 
 
Figure 1. Human Intestinal T cells are responsive to IFN-1 in health and IBD. A-
B Intestinal samples were isolated from controls (n=8) or IBD patients (n=10) in the 
presence of IFN-1 for 24 hours or Unstimulated (US) and cells were sorted for CD3+ 
viable cells. RNA was extracted and expression of ISGs MxA (A) and 2’5’OAS (B) 
were measured by qRT-PCR.C Representative flow cytometry plots of cells isolated 
by walk out. Cells were stimulated (lower panel) or not (upper panel) IFN-1 for 15 
minutes. D Combined results of controls (n=16) and IBD patients (n=24) showing 
frequency of pSTAT1+ CD4+ T cells with IFN-1 stimulation or not (US). White boxes 
indicate 1st to 3rd quartiles with middle line indicating median value. E-F Fresh frozen 
sections prepared from control colon tissue for immunohistochemistry. CD3 as green 
(AF488). E isotype staining  mIgG1 (AF555 - red). F IFNβ (AF555 – red). 
Representative of 5 independent experiments. 
 
Figure 2 Endogenous IFN-1 supports U-STAT1 expression and IFN-1:pSTAT1 
responsiveness in human intestinal CD4+ T cells. A-D LPMCs were walked-out 
in the presence of anti-IFNβ antibody or isotype control. Cells were analysed by flow 
cytometry gated on scatter and CD4+. A Expression (total) (U-)STAT1 in CD4+ 
intestinal T cells (n=20).  B As per A, showing paired values from control samples 
only (n=8). C pSTAT1 expression in CD4+ intestinal t cells (n=20). D As per C, 
showing paired values from control samples only (n=8).  
 
Figure 3 Intestinal T cells are more responsive to IFN-1 in IBD, not simply due 
to an increase Th1 phenotype.  LPMCs were isolated by walk-out and processed 
for phosflow (A-C) or intestinal T cells were flow sorted and mRNA processed for 
qRT-PCR (D-F). A Representative flow cytometry plot of pSTAT1 expression in T-
bet+ (black line) and T-bet- (grey line) gated on CD4+ T cells (dotted line mIgG2A 
isotype). B 2D representative FACS plot of CD4+ T cells showing co-expression of 
T-bet and pSTAT1. C Proportion of all T-Bet+CD4+ T cells that are also pSTAT1+ 
(n=23). Grey line indicates median. D-E Expression of ISGs MxA (D) and 2’5’ OAS 
(E) after 24 hours walk-out cell isolation in the presence of IFN-1, comparing the 
samples with IFN-1 to those without in controls (n=8) and IBD (n=10) F Intestinal T 
cells were isolated immediately by collagenase digestion before RNA extraction. 
Expression of SOCS1 from controls (n=8) and IBD (n=10). Bars indicate median 
expression with lines indicating standard deviation.  
 
Figure 4. IBD-associated alteration in STAT phosphorylation are specific for 
STAT1 and are not seen in the peripheral blood. A Walk out cells were isolated 
from controls (n=16) or IBD patients (n=24), and either stimulated with IFN-1 for 15 
minutes or not (US). The percentage of pSTAT3 + (left) or pSTAT5+ (right) CD4+ T 
cells are shown. B. PBMCs were isolated from IBD patients (n=18) and age matched 
controls (8). Cells were analysed for pSTAT1 signal after 15 minute stimulation with 
IFN-1, depending on T cells subset, CD3+CD4+CD45RA-β7-(memory β7-) 
CD3+CD4+CD45RA-β7+ (memory β7+) or CD3+CD4+CD45RA+ (naive).   
 
Figure 5 IFNβ neutralization decreases IL-10 production from intestinal CD4+ T 
cells in healthy controls, but increases multiple cytokines in samples from 
non-inflamed IBD samples. LPMCs were isolated in the presence of anti-IFNβ or 
isotype control (mIgG1). LPMCs were then collected and stimulated with CD3/CD28 
antibodies for 24 hours. Intracellular cytokines or transcitpion factors were measured 
by flow cytometry as follows: A T-bet, B FoxP3 C IL-10, D IFNγ E TNFα and F IL-17. 
Cells were gated on scatter and CD4+  
 
Figure 6 IFNβ neutralisation increases IFNγ concentrations in supernatants 
from control mucosa, but increased IL-10 concentrations from non-IBD 
mucosa. Cells were isolated in the presence of neutralising anti-IFNβ antibody or 
isotype control (mIgG1). The supernatant was collected and IL-10 (A), IFNγ (B), 
TNFα (C), IL-17 (D), and IFNα and were measured by multiplex ELISA (n=11 
controls, n=11 IBD)  
 
 
 
Supplementary Figures 
 
Supplemental figure 1. IFNβ was detectable in the lamina propria of control 
colon. Fresh frozen sections prepared from control colon tissue for 
immunohistochemistry. CD3 as green (AF488). A isotype staining  mIgG1 (AF555 - 
red) in control sample. B IFNβ (AF555 – red). C isotype in control with lymphoid 
follicle seen. D IFN in lymphoid follicle (same as C) Representative of 5 independent 
experiments 
 
 
Supplemental figure 2. Most Walk-out cells are memory and these are the 
responsive cells. A CD4+ T cells are shown demonstrated CD45RA staining. B 
CD45RA+ (naive) or C CD45RA- (memory) CD4+ T cells after IFN-1 stimulation. D 
pSTAT1+ expression in gated CD4+ intestinal T cells based on CD45RA expression. 
Representative of 7 experiments. Statistical analysis by paired t test. 
 
Supplemental figure 3. T cell activation marker CD69 is only seen in memory 
cells and correlates with pSTAT1 expression. A Representative FACS plot of 
gated CD4+ walk-out intestinal T cells showing CD45RA and CD69 co-expression. B 
CD45RA-CD69+ and C CD45RA-CD69+ showing pSTAT1 expression after IFN-1 
stimulation. Representative of 7 experiments. D Combined data comparing pSTAT1+ 
frequency in gated CD4+ intestinal T cells between CD69+ and CD69- cells. 
Statistical analysis by paired t test. 
 
Supplementary figure 4. Expression of pSTAT1 is more frequent in Intestinal T 
cells from non-inflamed areas in IBD patients.  Intestinal biopsies of IBD patients 
(normal macro/microscopically – Non-Inflamed or Inflamed), were processed by the 
walk out method. A,B Percentage of pSTAT1+ CD4+ T cells in IBD (n=24) patients in 
both unstimulated (A) and after 15 minute stimulation with IFN-1 (B). C Total STAT1 
expression (phosphorylated and non-phosphorylated; U-STAT1+) as a percentage of 
intestinal CD4+ in unstimulated samples and D U-STAT1 Mean Fluorescence 
Intensity (MFI) levels from the same samples.  Boxes indicate 1st and 3rd quartiles, 
with the middle line the median. Statistical analysis by paired t test  
 
 
Supplemental figure 5. pSTAT1 expression is not solely representative of a 
TH1 phenotype. Expression of transcription factors T-Bet (A) and FoxP3 (B) as a 
percentage of all walk-out CD4+ T cells from control (n=10) or Non-inflamed (n=12) 
or inflamed (n=12) IBD samples. 
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